세계의 당뇨병 케어 디바이스 시장 규모는 2023년에 320억 달러에 달했습니다. 향후 IMARC Group은 시장이 2032년까지 593억 달러에 달하며, 2024-2032년 7%의 성장률(CAGR)을 보일 것으로 예측하고 있습니다. 당뇨병 유병률 증가, 급속한 기술 발전, 유리한 정부 구상 부과, 가처분 소득 증가, 빅데이터 및 분석의 통합, 노인 인구 증가 등이 시장을 촉진하는 주요 요인 중 일부입니다.
당뇨병 케어 디바이스는 당뇨병의 모니터링과 관리를 돕기 위해 고안된 특수 의료기기를 말합니다. 혈당 측정기, 인슐린 펌프, 케톤체 측정기, 인슐린 펜, 자동 인슐린 전달(AID) 시스템, 인슐린 제트 주사기 등이 포함됩니다. 당뇨병 관리 장비는 혈당 자가 측정, 인슐린 투여, 데이터 추적, 소아 관리, 임신성 당뇨병 관리, 노인 관리, 운동 계획, 식단 수정, 응급 상황 등에 널리 사용되고 있습니다. 혈당 조절을 개선하고, 치료 순응도를 높이고, 합병증을 최소화하는 데 도움이 되는 신뢰할 수 있고 사용하기 쉬운 기기입니다.
가처분 소득이 증가함에 따라 더 많은 사람들이 정교한 당뇨병 케어 디바이스를 구매할 수 있게 되면서 시장 성장을 촉진하고 있습니다. 이와 더불어, 라이프스타일의 변화로 인해 도시 지역 전반에서 당뇨병 위험이 증가하면서 시장 성장을 가속하고 있습니다. 또한 당뇨병 케어 디바이스에 빅데이터와 분석이 통합되어 보다 스마트하고 데이터베이스의 치료 계획을 수립할 수 있게된 것도 시장 성장에 기여하고 있습니다. 또한 자가 모니터링의 확산과 함께 사용자 친화적이고 빠르고 사용하기 쉬운 기기에 대한 수요가 증가하고 있는 것도 시장 성장에 긍정적인 영향을 미치고 있습니다. 이와는 별도로, 소비자가 다양한 브랜드의 당뇨병 케어 디바이스를 경쟁력 있는 가격으로 쉽게 구매할 수 있는 소매 플랫폼의 확산이 시장 성장을 지원하고 있습니다. 또한 당뇨병 및 기타 만성질환에 취약한 노인 인구 증가는 또 다른 성장 촉진요인으로 작용하고 있습니다.
당뇨병 유병률 상승
당뇨병 발병률 증가는 당뇨병 케어 디바이스 시장을 촉진하는 주요 요인입니다. 이러한 증가의 주요 원인은 앉아서 생활하는 습관과 고당, 고지방 식단의 섭취 증가 등 다양한 생활습관 변화에 기인합니다. 또한 당뇨병 환자 수가 증가함에 따라 효율적인 관리 및 모니터링 툴의 필요성이 그 어느 때보다 중요해지고 있습니다. 이에 따라 당뇨병 케어 디바이스는 포도당 관리를 개선하고, 합병증 위험을 최소화하며, 응급의료 방문을 줄이고, 환자 결과를 개선하고, 신속한 의사 결정을 위한 실시간 데이터를 제공하기 위해 널리 사용되고 있습니다. 또한 당뇨병 유병률이 높아짐에 따라 당뇨병에 대한 인식과 시급성이 높아져 기술 발전 속도를 가속화하기 위한 연구 및 혁신 노력에 대한 투자를 촉진하고 잠재적 구매자에게 시장의 매력을 더욱 높여주고 있습니다.
급격한 기술 발전
당뇨병 케어 디바이스 시장은 정확성, 사용 편의성 및 편의성을 향상시키는 급속한 기술 발전으로 인해 시장이 형성되고 있습니다. 이에 따라 실시간 혈당 모니터링을 제공하고 더 나은 치료 맞춤화와 생활습관 조정을 가능하게 하는 연속 혈당 모니터링(CGM) 시스템의 도입은 시장 성장에 긍정적인 영향을 미치고 있습니다. 또한 인슐린 투여시 추측을 배제할 수 있는 고도로 정교한 용량 계산기가 탑재된 스마트 인슐린 펜의 도입은 시장 성장에 기여하고 있습니다. 또한 의료진과 환자 간의 원활한 데이터 공유를 가능하게 하는 커넥티비티 기능을 갖춘 혁신적인 디바이스 시장 개척은 시장 성장에 긍정적인 영향을 미치고 있습니다.
우호적인 정부 구상 부여
공중 보건 정책과 정부의 구상은 당뇨병 케어 디바이스 시장의 성장에 중요한 역할을 하고 있습니다. 일부 정부는 당뇨병이 의료 시스템에 미치는 부담을 인식하고 이를 해결하기 위해 적극적으로 노력하고 있습니다. 이에 따라 당뇨병의 위험과 관리에 대해 대중을 교육하는 것을 목표로 하는 인식 개선 캠페인이 개최되어 시장 성장에 기여하고 있습니다. 또한 당뇨병 케어 디바이스 비용을 보조하기 위한 여러 정부의 예산 배분이 증가하여 더 많은 사람들이 더 쉽게 이용할 수 있게된 것도 시장 성장에 기여하고 있습니다. 이 외에도 지속적인 혈당 모니터링(CGM)과 같은 고급 장비의 비용을 충당하기 위해 다양한 상환 제도의 도입이 시장 성장에 기여하고 있습니다.
The global diabetes care devices market size reached US$ 32.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 59.3 Billion by 2032, exhibiting a growth rate (CAGR) of 7% during 2024-2032. The rising incidences of diabetes, rapid technological advancements, imposition of favorable government initiatives, increasing disposable incomes, integration of big data and analytics, and escalating geriatric population are some of the major factors propelling the market.
Diabetes care devices refer to specialized medical equipment designed to assist in the monitoring and management of diabetes. It includes blood glucose meters, insulin pumps, ketone meters, insulin pens, automated insulin delivery (AID) systems, and insulin jet injectors. Diabetes care devices are widely used for self-monitoring of blood glucose, insulin dosing, data tracking, pediatric care, gestational diabetes management, geriatric care, exercise planning, diet modification, and emergency situations. They are reliable and user-friendly devices that aid in improving glucose control, adhering to treatment, and minimizing complications.
The increasing disposable incomes, which are enabling more individuals to afford sophisticated diabetes care devices, are propelling the market growth. Besides this, the rising risk of diabetes across urban areas due to lifestyle changes is favoring the market growth. Additionally, the integration of big data and analytics in diabetes care devices, which allows for smarter, data-driven treatment plans, is contributing to the market growth. Furthermore, the growing demand for user-friendly, quick, and easy-to-use devices, owing to the increasing adoption of self-monitoring practices, is positively influencing the market growth. Apart from this, the proliferation of retail platforms, which allows consumers to easily access diabetes care devices from various brands at competitive prices, is supporting the market growth. Moreover, the escalating geriatric population, which is highly susceptible to diabetes and other chronic illnesses, is acting as another growth-inducing factor.
The rising incidence of diabetes
The growing prevalence of diabetes is a dominant factor fueling the diabetes care devices market. This escalation is primarily caused by various lifestyle changes, including sedentary habits and increasing consumption of high-sugar and high-fat diets. Furthermore, as the number of diabetes cases multiplies, the need for efficient management and monitoring tools becomes more critical than ever. In line with this, diabetes care devices are widely used to improve glucose management, minimize the risks of complications, reduce emergency healthcare visits, increase patient outcomes, and provide real-time data for quick decision-making. Moreover, the high incidence rates lead to greater awareness and urgency, thereby encouraging more investments in research and innovation efforts to accelerate the pace of technological advancements, making the market even more attractive to potential buyers.
The rapid technological advancements
The diabetes care devices market is being shaped by rapid technological advancements that offer improved precision, ease of use, and convenience. In line with this, the introduction of continuous glucose monitoring (CGM) systems, which provide real-time glucose monitoring, allowing for better treatment customization and lifestyle adjustments, is positively influencing the market growth. Furthermore, the introduction of smart insulin pens equipped with dose calculators, which offer a high level of sophistication, thus eliminating the guesswork in insulin dosing, is contributing to the market growth. Additionally, the development of innovative devices that are equipped with connectivity features, enabling seamless data sharing between healthcare professionals and patients, is favoring the market growth.
The imposition of favorable government initiatives
Public health policies and government initiatives play a significant role in the growth of the diabetes care devices market. Several governments are recognizing the burden that diabetes imposes on healthcare systems and are taking proactive measures to address it. In line with this, the organization of awareness campaigns aimed at educating the public about diabetes risks and management is contributing to the market growth. Moreover, the increasing allocation of funds by several governments to subsidize the cost of diabetes care devices, making them more accessible to a broader population, is contributing to the market growth. Besides this, the introduction of various reimbursement schemes to cover the cost of advanced devices, such as continuous glucose monitoring (CGMs) is contributing to the market growth.
IMARC Group provides an analysis of the key trends in each segment of the global diabetes care devices market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on type, distribution channel and end user.
Blood Glucose Monitoring (BGM) Devices
Self-Monitoring Devices
Continuous Glucose Monitoring Devices
Insulin Delivery Devices
Pumps
Pens
Syringes
Jet Injectors
Blood glucose monitoring (BGM) devices dominate the market
The report has provided a detailed breakup and analysis of the market based on type. This includes blood glucose monitoring (BGM) devices (self-monitoring devices and continuous glucose monitoring devices) and insulin delivery devices (pumps, pens, syringes, and jet injectors). According to the report, blood glucose monitoring (BGM) devices represented the largest segment.
Blood glucose monitoring (BGM) devices are dominating the market as they are highly affordable, making them accessible to a broader range of consumers. Furthermore, they are designed for user-friendliness, often requiring just a small drop of blood for accurate glucose readings. Additionally, BGM devices offer near-instantaneous results, enabling immediate action if needed, such as adjusting insulin dosage or food intake. Besides this, they are compact and easy to carry, making them convenient for people who are always on the go. This portability ensures that monitoring can happen anytime, anywhere. Moreover, BGM devices are being used for a longer period and enjoy broad acceptance among healthcare providers. In addition, they require minimal upkeep, usually replacement of test strips and occasional calibration, which makes them convenient for long-term use.
Hospital Pharmacies
Retail Pharmacies
Diabetes Clinics/Centers
Online Pharmacies
Others
Hospital pharmacies hold the largest share in the market
A detailed breakup and analysis of the market based on the distribution channel has also been provided in the report. This includes hospital pharmacies, retail pharmacies, diabetes clinics/Centers, online pharmacies, and others. According to the report, hospital pharmacies accounted for the largest market share.
Hospital pharmacies are dominating the market as they are considered reliable and trustworthy sources for medical devices, including those for diabetes care. Furthermore, patients admitted for diabetes complications or those visiting for a routine check-up can quickly and conveniently purchase the required devices and supplies from the hospital pharmacy. In addition, they employ well-trained pharmacists who can provide expert advice on device usage, thereby adding an extra layer of reassurance for patients. Besides this, products sold in hospital pharmacies are generally subject to rigorous quality checks, ensuring that patients receive authentic and effective devices. Moreover, they offer a streamlined process for insurance claims and reimbursements, making it easier for patients to offset the costs of their diabetes care devices. Along with this, hospital pharmacies offer a comprehensive range of diabetes care devices, giving patients various options to choose from.
Hospitals
Homecare
Diagnostic Centers
Ambulatory Surgery Centers
Hospitals hold the largest share in the market
A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, homecare, diagnostic centers, and ambulatory surgery centers. According to the report, hospitals accounted for the largest market share.
Hospitals are dominating the market as they offer a one-stop solution for all medical needs, making it easier for patients to get all their diabetes-related services, including consultations, treatments, and devices. Furthermore, they employ specialists in endocrinology and diabetes care, ensuring that patients receive expert advice and treatment. In addition, hospitals have the resources to handle diabetes-related emergencies, such as diabetic ketoacidosis, which standalone clinics may not be equipped for. Apart from this, hospital-based care is often covered by insurance plans, making it a more accessible option for many patients. Moreover, the sheer number of patients that hospitals serve ensures that they purchase diabetes care devices in bulk, thus contributing to their large share of the market. Along with this, they are subjected to strict quality control standards, which provide assurance of the efficacy and safety of the diabetes care devices used.
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
North America exhibits a clear dominance, accounting for the largest diabetes care devices market share
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America has one of the highest rates of diabetes in the world, which leads to increased demand for diabetes care devices. Furthermore, the region boasts a well-developed healthcare system with widespread availability of advanced medical technologies, including diabetes care devices. Additionally, the presence of comprehensive insurance plans, which cover diabetes treatment and devices, making it convenient for patients to access the care they need, is positively influencing the market growth. Besides this, North America hosts some of the leading companies in medical device manufacturing that are continuously updating and advancing diabetes care technology. In addition, the escalating awareness about diabetes and its management among regional consumers is acting as another growth-inducing factor. Moreover, the imposition of supportive policies and initiatives by regional governments to combat diabetes and provide access to high-quality treatment is favoring the market growth.
Leading companies are striving to introduce advanced devices, such as smart insulin pens, integrated continuous glucose monitoring (CGM) systems, and more accurate blood glucose meters. Furthermore, they are entering into partnerships with healthcare organizations, tech firms, and even competitors to co-develop new technologies. Besides this, major players are developing customized products to target emerging markets where diabetes is becoming more prevalent. Additionally, they are integrating digital technologies, such as data analytics and telehealth, into their devices to allow real-time monitoring and data collection, which can be crucial for effective diabetes management. Moreover, several companies are investing in education programs and materials to help users understand how to manage diabetes effectively. Along with this, they are leveraging online platforms for direct sales and customer engagement.
Abbott Laboratories
ACON Laboratories Inc.
Ascensia Diabetes Care Holdings AG (PHC Holdings Corporation)
Becton Dickinson and Company
Bionime Corporation
Dexcom Inc.
F. Hoffmann-La Roche AG
Johnson & Johnson
Medtronic plc
Novo Nordisk A/S
Sinocare Inc.
Terumo Corporation
In February 2020, Abbott Laboratories was granted approval by the U.S. Food and Drug Administration (FDA) to utilize the FreeStyle Libre 14-day Flash glucose monitoring systems within hospital settings.
In April 2021, Medtronic Plc introduced the Medtronic Extended Infusion set in selected European countries, which can be worn for up to 7 days.
In November 2022, Ascensia Diabetes Care Holdings AG announced the integration of the Eversense CGM system with Apple Health.